以核酸适体KMF2-1a为基础的乳腺癌细胞靶向化疗药物载体研究

目的:探讨开发以核酸适体KMF2-1a为基础的乳腺癌细胞靶向阿霉素载体的可行性.方法:应用流式细胞仪检测人乳腺癌MCF-10AT1细胞对核酸适体KMF2-1a及其修饰物(药物载体)的内吞作用；将阿霉素与药物载体相互作用后,用分光光度计检测阿霉素嵌入药物载体的情况.结果:流式细胞仪检测示,核酸适体KMF2-1a及其修饰物均能被MCF-10AT1细胞特异内吞；分光光度仪检测示,阿霉素可成功嵌入至药物载体中.结论:核酸适体KMF2-1a能被MCF-10AT1细胞特异内吞,经修饰后有可能作为阿霉素的载体用于乳腺癌的靶向治疗.

Aptamer KMF2-1a-based chemotherapeutic drug carrier targeting breast cancer cells

Objective: To investigate the feasibility of the development of aptamer KMF2-1a-based doxorubicin carrier that targets breast cancer cells.Methods: The internalization efficacies of aptamer KMF2-1a and its modified product (drug carrier) into human breast cancer MCF-10AT1 cells were tested by flow cytometry analysis. The incorporation of doxorubicin into the drug carrier was determined by spectrophotometer analysis after their interaction. Results: Flow cytometry analysis showed that both aptamer KMF2-1a and its modified product could be specifically internalized by MCF-10AT1 cells. Spectrophotometer detection demonstrated that doxorubicin was successfully incorporated into the drug carrier.Conclusion: Aptamer KMF2-1a can be internalized specifically by MCF-10AT1 cells, and it can be potentially used as a doxorubicin carrier after modification for targeted breast cancer therapy.